# NMN vs NR: Comparing NAD+ Precursors in the Research | NAD+ > NMN vs NR: how the two leading NAD+ precursors differ in uptake, salvage route, and human-trial evidence. A cited digest — not a product comparison. Why most oral "NAD+" is really a precursor — and how nicotinamide mononucleotide and nicotinamide riboside differ in route, uptake, and trial evidence. ## The short version **NMN vs NR** is the comparison most "NAD+" shoppers are actually making without realizing it. NAD+ itself is too big and charged to absorb well by mouth, so oral products are *precursors* — building blocks the body converts into NAD+. The two front-runners are NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside). Both reliably raise blood NAD+ in trials. They differ in the chemical step they enter: NR is converted to NMN by dedicated kinases, then on to NAD+; NMN sits one step closer to the finish line. Think of it as two players reaching the same goal by slightly different routes. This page reads the human evidence for each side by side — and keeps NAD+ itself separate from both. ## Why oral "NAD+" is usually a precursor NAD+ is a large, charged dinucleotide (663.43 Da), and it is not freely taken up intact by most cells [5]. That is the practical reason the oral market runs on precursors: smaller molecules the body can absorb and then assemble into NAD+. The two dominant oral precursors are nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR). Both feed the salvage pathway, the dominant route of NAD+ synthesis in mammals, which recycles nicotinamide back into NAD+ via the rate-limiting enzyme NAMPT [5][14]. The routes differ by one enzymatic step. NR is first phosphorylated to NMN by nicotinamide riboside kinases (NRK1/NRK2), then converted onward to NAD+ — a Preiss-Handler-independent entry whose structural basis was worked out from crystal structures of human Nrk1 [13]. NMN sits one step further along, directly adjacent to NAD+ in the salvage sequence. That single-step difference is the heart of the NMN-vs-NR debate. ## NMN in human trials Nicotinamide mononucleotide (NMN) has accumulated several controlled human trials. In prediabetic, postmenopausal women, 250 mg/day of oral NMN for 10 weeks significantly increased muscle insulin sensitivity (measured by hyperinsulinemic-euglycemic clamp) and remodeled insulin signaling, though body composition and HbA1c did not change [1]. In a larger multicenter double-blind RCT, NMN at 300-900 mg/day for 60 days dose-dependently raised blood NAD+ versus placebo and improved walking distance and quality-of-life scores, with 600 mg/day identified as the optimal dose and no safety issues at any dose [3]. So NMN reliably raises blood NAD+ and has produced some functional signals — within trials that remain modest in size and duration. ## Nicotinamide riboside (NR), the most-studied oral precursor Nicotinamide riboside (NR) is the most clinically studied oral NAD+ booster. In a randomized, double-blind, placebo-controlled trial in healthy overweight adults, NR at 100, 300, and 1000 mg/day for eight weeks raised whole-blood NAD+ by 22%, 51%, and 142% respectively — a clean dose-response maintained throughout the study, with no flushing and no significant adverse-event difference from placebo [4]. NR did not elevate LDL cholesterol or disrupt one-carbon metabolism [4]. Its conversion route — NR to NMN via NRK kinases, then to NAD+ — is structurally well characterized [13]. The depth of NR's controlled dose-response data is the main thing distinguishing it from NMN in the published record. ## NAD+ itself vs its precursors The cleanest way to read this field is to keep three things separate. NAD+ itself is the finished coenzyme, poorly absorbed by mouth and not freely taken up intact by cells [5]. NMN and NR are precursors — smaller building blocks the body converts into NAD+ — and they are what most oral "NAD+" products actually contain [4]. Describing a study of oral NMN or NR as "taking NAD+" is inaccurate; the trials dosed the precursor and measured the resulting NAD+. This distinction is not pedantry — it is the difference between what was administered and what was measured. ## Is taking NAD orally effective? NAD+ itself is large and charged and poorly absorbed intact, so oral products are usually precursors (NMN, NR), which reliably raise blood NAD+ in trials [4][3]. Effects on hard clinical endpoints are more mixed: a 2025 review concluded human efficacy data remain limited [15]. "Effective" at raising blood NAD+ is well supported; "effective" at changing health outcomes is not yet established. --- An arcade-console reading of the NAD+ literature — the coenzyme logged apart from its precursors NMN and NR, the blood-NAD+ the trials actually moved scored against the gaps the rodent and IV data leave open; no clinic behind the console, nothing here infused, ordered, or sold.